Trial Profile
A multicentre, prospective observation post-authorisation, open-label study of sublingual fentanyl tablets for relief of breakthrough pain in cancer patients and association with quality of life outcomes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2019
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- 08 Jun 2019 Results of sub-group analysis of two categories [patients aged between 65 and 74 years (low age group) and patients aged 75 years and over (high age group)] assessing efficacy and tolerability of Fentyl sublingual tablets in cancer pain patients, published in the Drugs in R and D.
- 31 Jul 2017 New trial record
- 25 Jul 2017 Results of subgroup (age more than or equal to 65 years and less than 65 years) analysis published in the Drugs in R and D